These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24438008)

  • 1. Use of tissue plasminogen activator in catheters used for extracorporeal renal replacement therapy.
    Langston C; Eatroff A; Poeppel K
    J Vet Intern Med; 2014; 28(2):270-6. PubMed ID: 24438008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteplase versus urokinase for occluded hemodialysis catheters.
    Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
    Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant tissue plasminogen activator (alteplase) for restoration of function to occluded central venous catheters in pediatric patients.
    Shen V; Li X; Murdock M; Resnansky L; McCluskey ER; Semba CP;
    J Pediatr Hematol Oncol; 2003 Jan; 25(1):38-45. PubMed ID: 12544772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteplase for the treatment of catheter occlusion in pediatric patients.
    Anderson DM; Pesaturo KA; Casavant J; Ramsey EZ
    Ann Pharmacother; 2013 Mar; 47(3):405-9. PubMed ID: 23463740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular access for extracorporeal renal replacement therapy in veterinary patients.
    Chalhoub S; Langston CE; Poeppel K
    Vet Clin North Am Small Anim Pract; 2011 Jan; 41(1):147-61. PubMed ID: 21251515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
    Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
    J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
    Little MA; Walshe JJ
    Am J Kidney Dis; 2002 Jan; 39(1):86-91. PubMed ID: 11774106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections.
    Rowan CM; Miller KE; Beardsley AL; Ahmed SS; Rojas LA; Hedlund TL; Speicher RH; Nitu ME
    Pediatr Crit Care Med; 2013 Mar; 14(3):306-9. PubMed ID: 23392362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
    Eyrich H; Walton T; Macon EJ; Howe A
    Am J Health Syst Pharm; 2002 Aug; 59(15):1437-40. PubMed ID: 12166043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occluded Tunneled Venous Catheter in Hemodialysis Patients: Risk Factors and Efficacy of Alteplase.
    Ponce D; Mendes M; Silva T; Oliveira R
    Artif Organs; 2015 Sep; 39(9):741-7. PubMed ID: 25894244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective use of alteplase for occluded tunneled venous catheter in hemodialysis patients.
    Mendes ML; Castro JH; Silva TN; Barretti P; Ponce D
    Artif Organs; 2014 May; 38(5):399-403. PubMed ID: 24117542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients.
    Semba CP; Deitcher SR; Li X; Resnansky L; Tu T; McCluskey ER;
    J Vasc Interv Radiol; 2002 Dec; 13(12):1199-205. PubMed ID: 12471182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant tissue plasminogen activator to restore catheter patency: efficacy and safety analysis from a multihospital NICU system.
    Scott DM; Ling CY; MacQueen BC; Baer VL; Gerday E; Christensen RD
    J Perinatol; 2017 Mar; 37(3):291-295. PubMed ID: 27831547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteplase infusion versus dwell for clearance of partially occluded central venous catheters in critically ill pediatric patients.
    Ragsdale CE; Oliver MR; Thompson AJ; Evans MC
    Pediatr Crit Care Med; 2014 Jul; 15(6):e253-60. PubMed ID: 24751787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of hospital length of stay, costs, and readmissions of alteplase versus catheter replacement among patients with occluded central venous catheters.
    Ernst FR; Chen E; Lipkin C; Tayama D; Amin AN
    J Hosp Med; 2014 Aug; 9(8):490-6. PubMed ID: 24825837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of tissue plasminogen activator infusion to re-establish function of tunneled hemodialysis catheters.
    Dowling K; Sansivero G; Stainken B; Siskin G; Dolen E; Ahn J; Mitchell N
    Nephrol Nurs J; 2004; 31(2):199-200. PubMed ID: 15114800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.
    Gittins NS; Hunter-Blair YL; Matthews JN; Coulthard MG
    Arch Dis Child; 2007 Jun; 92(6):499-501. PubMed ID: 17068072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tip Design of Hemodialysis Catheters Influences Thrombotic Events and Replacement Rate.
    Petridis C; Nitschke M; Lehne W; Smith E; Goltz JP; Lehnert H; Meier M
    Eur J Vasc Endovasc Surg; 2017 Feb; 53(2):262-267. PubMed ID: 27876561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters.
    Daeihagh P; Jordan J; Chen J; Rocco M
    Am J Kidney Dis; 2000 Jul; 36(1):75-9. PubMed ID: 10873875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
    Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
    Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.